Blood test could warn cancer patients of chemo nerve damage

NCT ID NCT06430814

Recruiting now Knowledge-focused Sponsor: University of Southern Denmark Source: ClinicalTrials.gov ↗

Summary

This study aims to find a way to predict which breast cancer patients are at high risk for developing severe nerve damage (neuropathy) from paclitaxel chemotherapy. Researchers will test if a specific protein in the blood, measured after the first treatment cycle, can identify patients who may need to stop treatment early due to this painful side effect. The goal is to help doctors personalize treatment and potentially prevent debilitating nerve pain before it becomes severe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Odense University Hospital
RECRUITING

Odense, 5000, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital of Southern Denmark, Sønderborg
RECRUITING

Sønderborg, 6400, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••
University Hospital of Southern Denmark, Vejle
RECRUITING

Vejle, 7100, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY